Related Experiment Video
Updated: Aug 22, 2025

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Plantamajoside attenuates cardiac fibrosis via inhibiting AGEs activated-RAGE/autophagy/EndMT pathway
Lu Zhang1,2,3,4, Yi-Ning Guo1,2,3,4, Jing Liu2,3
1Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, China.
Abstract:
Advanced glycation end products (AGEs) have been identified to transduce fibrogenic signals via inducing the activation of their receptor (RAGE)-mediated pathway. Recently, disrupting AGE-RAGE interaction has become a promising therapeutic strategy for chronic heart failure (CHF). Endothelial-to-mesenchymal transition (EndMT) is close to the cardiac fibrosis pathological process. Our previous studies have demonstrated that knockout RAGE suppressed the autophagy-mediated EndMT, and thus alleviated cardiac fibrosis. Plantamajoside (PMS) is the major bioactive compound of Plantago Asiatica, and its activity of anti-fibrosis has been documented in many reports. However, its effect on CHF and the underlying mechanism remains elusive. Thus, we tried to elucidate the protective role of PMS in CHF from the viewpoint of the AGEs/RAGE/autophagy/EndMT axis. Herein, PMS was found to attenuate cardiac fibrosis and dysfunction, suppress EndMT, reduce autophagy levels and serum levels of AGEs, yet did not affect the expression of RAGE in CHF mice. Mechanically, PMS possibly binds to the V-domain of RAGE, which is similar to the interaction between AGEs and RAGE. Importantly, this competitive binding disturbed AGEs-induced the RAGE-autophagy-EndMT pathway in vitro. Collectively, our results indicated that PMS might exert an anti-cardiac fibrosis effect by specifically binding RAGE to suppress the AGEs-activated RAGE/autophagy/EndMT pathway.
Insights
Plantamajoside (PMS) combats cardiac fibrosis in chronic heart failure (CHF) by blocking the AGEs/RAGE/autophagy/EndMT pathway. This natural compound offers a potential therapeutic strategy for heart conditions.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Advanced glycation end products (AGEs) signal through receptor for AGEs (RAGE), promoting fibrotic diseases.
- Disrupting the AGE-RAGE interaction is a therapeutic target for chronic heart failure (CHF).
- Endothelial-to-mesenchymal transition (EndMT) is implicated in cardiac fibrosis, and RAGE activation mediates this process via autophagy.
Purpose of the Study:
- To investigate the protective role of Plantamajoside (PMS) in CHF.
- To elucidate the underlying mechanism of PMS action on the AGEs/RAGE/autophagy/EndMT axis.
- To determine if PMS can attenuate cardiac fibrosis and dysfunction in a mouse model of CHF.
Main Methods:
- Administered PMS to mice with experimentally induced CHF.
- Assessed cardiac function, fibrosis, and EndMT markers.
- Measured autophagy levels and serum AGEs.
- Investigated PMS binding to RAGE in vitro and its effect on the AGEs-RAGE-autophagy-EndMT pathway.
Main Results:
- PMS attenuated cardiac fibrosis and dysfunction in CHF mice.
- PMS suppressed EndMT and reduced autophagy and serum AGEs levels.
- PMS competitively bound to the V-domain of RAGE, inhibiting the AGEs-induced RAGE-autophagy-EndMT pathway in vitro.
Conclusions:
- Plantamajoside (PMS) demonstrates anti-fibrotic effects in CHF.
- PMS acts by competitively inhibiting the AGEs-activated RAGE/autophagy/EndMT pathway.
- PMS represents a potential therapeutic agent for treating cardiac fibrosis in CHF.

